Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02272855 · ClinicalTrials.gov registry record · Phase 2

A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma

A Phase 2 study of Malignant Melanoma, sponsored by Takara Bio.

Completed
Registry status
Phase 2
Development phase
46
Enrollment target
8
Study locations

NCT02272855 is a Phase 2 study of Malignant Melanoma that has completed, run by Takara Bio. The registered enrollment target is 46 participants, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (75% lower). The trial reports 8 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02272855, a Phase 2 study of Malignant Melanoma, has completed, sponsored by Takara Bio.

COMPLETED
Registry status
Phase 2
Development phase
46 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.

Conditions Studied

Malignant Melanoma

Interventions

  • BIOLOGICAL HF10 plus Ipilimumab

Study Locations (8)

Pennsylvania

  • Clinical Site - Bethlehem
  • Clinical Site - Hershey

Texas

  • Clinical Site - Dallas
  • Clinical Site - Houston

California

  • Clinical Site - San Francisco

Georgia

  • Clinical Site - Atlanta

Oregon

  • Clinical Site - Portland

Utah

  • Clinical Site - Salt Lake City

Trial Details

FieldValue
Enrollment Target 46 participants
Start Date 2014-04-30
Est. Completion 2018-08
Phase Phase 2

Sponsor

Takara Bio

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02272855

The ClinicalTrials.gov registry entry for NCT02272855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 182-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (75% lower). The listed sponsor is Takara Bio, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which HF10 plus Ipilimumab is the first listed.

NCT02272855 reports 8 study locations spanning 6 distinct geographic areas - top geographies include Pennsylvania, Texas, California.

Frequently Asked Questions

What is clinical trial NCT02272855 about?

NCT02272855 is a clinical study titled "A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma". The purpose of this study is to determine if HF10 in combination with ipilimumab is effective in patients with stages IIIB, IIIC, or IV unresectable or metastatic melanoma.

What is the current status of trial NCT02272855?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 46 participants. The study started on 2014-04-30. Estimated completion is 2018-08.

What conditions does trial NCT02272855 study?

This clinical trial studies the following conditions: Malignant Melanoma.

What interventions are being tested in trial NCT02272855?

The interventions under investigation include: HF10 plus Ipilimumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT02272855?

This trial is sponsored by Takara Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02272855 being conducted?

This trial has 8 study locations across California, Georgia, Oregon, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Malignant Melanoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Malignant Melanoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.